NAD + Metabolism in Cardiac Health, Aging, and Disease

Author:

Abdellatif Mahmoud123ORCID,Sedej Simon14ORCID,Kroemer Guido235ORCID

Affiliation:

1. Department of Cardiology, Medical University of Graz, Austria (M.A., S.S.).

2. Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France (M.A., G.K.).

3. Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, Institut national de la santé et de la recherche médicale (INSERM) U1138, Institut Universitaire de France (M.A., G.K.).

4. Institute of Physiology, Faculty of Medicine, University of Maribor, Slovenia (S.S.).

5. Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance Publique – Hôpitaux de Paris (AP-HP), Paris 7015, France (G.K.).

Abstract

Nicotinamide adenine dinucleotide (NAD + ) is a central metabolite involved in energy and redox homeostasis as well as in DNA repair and protein deacetylation reactions. Pharmacological or genetic inhibition of NAD + -degrading enzymes, external supplementation of NAD + precursors, and transgenic overexpression of NAD + -generating enzymes have wide positive effects on metabolic health and age-associated diseases. NAD + pools tend to decline with normal aging, obesity, and hypertension, which are all major risk factors for cardiovascular disease, and NAD + replenishment extends healthspan, avoids metabolic syndrome, and reduces blood pressure in preclinical models. In addition, experimental elevation of NAD + improves atherosclerosis, ischemic, diabetic, arrhythmogenic, hypertrophic, or dilated cardiomyopathies, as well as different modalities of heart failure. Here, we critically discuss cardiomyocyte-specific circuitries of NAD + metabolism, comparatively evaluate distinct NAD + precursors for their preclinical efficacy, and raise outstanding questions on the optimal design of clinical trials in which NAD + replenishment or supraphysiological NAD + elevations are assessed for the prevention or treatment of major cardiac diseases. We surmise that patients with hitherto intractable cardiac diseases such as heart failure with preserved ejection fraction may profit from the administration of NAD + precursors. The development of such NAD + -centered treatments will rely on technological and conceptual progress on the fine regulation of NAD + metabolism.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Cited by 83 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3